Physician profile
Christopher Doan
NPI 1609279728
$6,259.69
in general payments reported to CMS, 2019-2025
22 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $142 · 2021: $394 · 2022: $919 · 2023: $1,278 · 2024: $1,609 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,395 · Entertainment: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,394.75 |
| Entertainment | $231.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $1,000.00 | 2024 | |
| Bausch & Lomb Americas INC. | $867.02 | 2022-2024 | Infuse, Infuse Multifocal, Revive |
| Alcon Vision LLC | $593.08 | 2019-2025 | Total30, Precision 1, Precision7 |
| Sun Pharmaceutical Industries INC. | $459.54 | 2023-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $457.25 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $374.98 | 2021 | |
| Dompe US, INC. | $275.88 | 2024-2025 | Oxervate |
| Abbvie INC. | $273.72 | 2022 | |
| Apellis Pharmaceuticals, INC. | $258.24 | 2025 | |
| Harrow Eye, LLC | $255.43 | 2025 | Vevye |
| Optos, INC. | $231.10 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $214.33 | 2024-2025 | Idosetr, Ce-Marked Kxla System |
| Johnson & Johnson Vision Care, INC. | $196.46 | 2022-2023 | Acuvue |
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $125.00 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $123.41 | 2023 | |
| Lkc Technologies, INC. | $119.21 | 2023 | |
| Aerie Pharmaceuticals, INC. | $90.68 | 2019 | |
| Ocular Therapeutix, INC. | $75.51 | 2022 | |
| Coopervision INC. | $69.08 | 2023 | Myday Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $39.25 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.